3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
13
Urinary Bladder Neoplasms
12
Neoplasms
10
Carcinoma, Renal Cell
9
Ovarian Neoplasms
7
Carcinoma, Transitional Cell
7
Neoplasm Metastasis
6
Pancreatic Neoplasms
5
Breast Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
4
Carcinoma, Merkel Cell
4
Triple Negative Breast Neoplasms
3
Recurrence
3
Lymphoma
3
Lung Neoplasms
3
Fallopian Tube Neoplasms
3
Colorectal Neoplasms
3
Stomach Neoplasms
2
Prostatic Neoplasms
2
Melanoma
2
Leukemia, Myeloid, Acute
2
Kidney Neoplasms
2
Kidney Diseases
2
Carcinoma, Ovarian Epithelial
2
Carcinoma, Hepatocellular
2
Urothelial Cancer
1
Urologic Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Turcot syndrome
1
Interventions
Carboplatin
42
Etoposide
37
Cisplatin
23
Topotecan
22
Nivolumab
17
pembrolizumab
12
atezolizumab
12
Ipilimumab
10
Paclitaxel
9
durvalumab
8
Irinotecan
8
Radiosurgery
6
Pemetrexed
6
rovalpituzumab tesirine
5
Magnetic Resonance Spectroscopy
5
trioctyl phosphine oxide
4
trilaciclib
4
etoposide phosphate
4
berzosertib
4
Sunitinib
4
Specimen Handling
4
Platinum
4
PM 01183
4
Dexamethasone
4
veliparib
3
tremelimumab
3
olaparib
3
carfilzomib
3
cabozantinib
3
Temozolomide
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Small Cell Lung Carcinoma
×
avelumab
×
Clear all
NCT02554812
2024-07-30
JAVELIN Medley
Pfizer
Phase 1/2
Terminated
409 enrolled
108 charts